JPWO2019222380A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019222380A5 JPWO2019222380A5 JP2020564095A JP2020564095A JPWO2019222380A5 JP WO2019222380 A5 JPWO2019222380 A5 JP WO2019222380A5 JP 2020564095 A JP2020564095 A JP 2020564095A JP 2020564095 A JP2020564095 A JP 2020564095A JP WO2019222380 A5 JPWO2019222380 A5 JP WO2019222380A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- human
- formula
- group
- alkylthioalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 12
- 125000004001 thioalkyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 9
- 125000003282 alkyl amino group Chemical group 0.000 claims 9
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 claims 9
- 125000004663 dialkyl amino group Chemical group 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 9
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001934 delay Effects 0.000 claims 2
- 125000005456 glyceride group Chemical group 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- 239000008180 pharmaceutical surfactant Substances 0.000 claims 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920002675 Polyoxyl Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 229960002446 octanoic acid Drugs 0.000 claims 1
- -1 polyoxyethylene Polymers 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024003447A JP7736825B2 (ja) | 2018-05-15 | 2024-01-12 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
| JP2025142520A JP2026000929A (ja) | 2018-05-15 | 2025-08-28 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671964P | 2018-05-15 | 2018-05-15 | |
| US62/671,964 | 2018-05-15 | ||
| PCT/US2019/032461 WO2019222380A1 (en) | 2018-05-15 | 2019-05-15 | Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024003447A Division JP7736825B2 (ja) | 2018-05-15 | 2024-01-12 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021524844A JP2021524844A (ja) | 2021-09-16 |
| JP2021524844A5 JP2021524844A5 (https=) | 2022-05-23 |
| JPWO2019222380A5 true JPWO2019222380A5 (https=) | 2022-05-23 |
| JP7421499B2 JP7421499B2 (ja) | 2024-01-24 |
Family
ID=66691010
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564095A Active JP7421499B2 (ja) | 2018-05-15 | 2019-05-15 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
| JP2024003447A Active JP7736825B2 (ja) | 2018-05-15 | 2024-01-12 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
| JP2025142520A Pending JP2026000929A (ja) | 2018-05-15 | 2025-08-28 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024003447A Active JP7736825B2 (ja) | 2018-05-15 | 2024-01-12 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
| JP2025142520A Pending JP2026000929A (ja) | 2018-05-15 | 2025-08-28 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210186972A1 (https=) |
| EP (2) | EP4721727A2 (https=) |
| JP (3) | JP7421499B2 (https=) |
| AU (2) | AU2019271208B2 (https=) |
| CA (1) | CA3100211A1 (https=) |
| ES (1) | ES3061722T3 (https=) |
| WO (1) | WO2019222380A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3532464A4 (en) | 2016-10-28 | 2020-07-08 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER |
| JP2020514252A (ja) | 2016-12-08 | 2020-05-21 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 |
| CA3092677A1 (en) | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| CA3104298A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| CN118908962A (zh) | 2019-05-06 | 2024-11-08 | 西奈山伊坎医学院 | 作为hpk1的降解剂的异双功能化合物 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| WO2022159650A1 (en) * | 2021-01-22 | 2022-07-28 | Icahn School Of Medicine At Mount Sinai | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF eEF1A2 |
| US20260028342A1 (en) * | 2022-07-29 | 2026-01-29 | The University Of North Carolina At Chapel Hill | Enhancing antimetastasis activity using targeted protein degradation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| CA2719803A1 (en) * | 2008-03-28 | 2009-10-01 | University Of Massachusetts | Compositions and methods for the preparation of nanoemulsions |
| TR201905480T4 (tr) * | 2008-04-18 | 2019-05-21 | Angiochem Inc | Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri. |
| EP2791142B1 (en) * | 2011-12-16 | 2019-07-03 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis |
| US9877966B1 (en) * | 2015-08-10 | 2018-01-30 | Eugene J. Oliva | Combination therapy for the inhibition of metastasis and tumorigenesis |
| TWI838700B (zh) * | 2015-09-30 | 2024-04-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
| US11241436B2 (en) * | 2017-01-25 | 2022-02-08 | Northwestern University | Autophagy inducers for treatment of CNS conditions |
-
2019
- 2019-05-15 JP JP2020564095A patent/JP7421499B2/ja active Active
- 2019-05-15 AU AU2019271208A patent/AU2019271208B2/en active Active
- 2019-05-15 ES ES19728226T patent/ES3061722T3/es active Active
- 2019-05-15 CA CA3100211A patent/CA3100211A1/en active Pending
- 2019-05-15 EP EP25214810.1A patent/EP4721727A2/en active Pending
- 2019-05-15 US US17/055,256 patent/US20210186972A1/en not_active Abandoned
- 2019-05-15 WO PCT/US2019/032461 patent/WO2019222380A1/en not_active Ceased
- 2019-05-15 EP EP19728226.2A patent/EP3793523B8/en active Active
-
2024
- 2024-01-12 JP JP2024003447A patent/JP7736825B2/ja active Active
- 2024-06-06 US US18/735,506 patent/US20240316056A1/en active Pending
-
2025
- 2025-05-12 AU AU2025203402A patent/AU2025203402A1/en active Pending
- 2025-08-28 JP JP2025142520A patent/JP2026000929A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021524844A5 (https=) | ||
| AU2002352105B2 (en) | Platinum derivative pharmaceutical formulations | |
| US5225404A (en) | Methods of treating colon tumors with tumor-inhibiting camptothecin compounds | |
| ES2279407T3 (es) | Combinaciones antineoplasicas. | |
| CZ290120B6 (cs) | Sdruľená kompozice paclitaxelu, docetaxelu nebo jejich analogu | |
| CA2423568A1 (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | |
| EP4003292A1 (en) | Soft chewable veterinary dosage form | |
| US20140120181A1 (en) | Composition comprising phosphatidylcholine as an active ingredient for attenuating toxicity of anticancer agent | |
| JPWO2019222380A5 (https=) | ||
| JP3208437B2 (ja) | 癌転移抑制剤 | |
| BG65913B1 (bg) | Използване на доцетаксел за лечение на хепатоцелуларен карцином | |
| US10220072B2 (en) | Mesalamine for the treatment of cancer | |
| KR100812693B1 (ko) | 항종양 효과 증강제 및 항종양제 | |
| KR100315890B1 (ko) | 전신염증및염증성간염치료용피리미딘누클레오티드전구체 | |
| JP2951407B2 (ja) | チアゾフリン及びリバビリンを用いる新生物病の処置方法 | |
| TWI760306B (zh) | 供治療癌症之口服投予紫杉醇及Ｐ-ｇｐ抑制劑的治療性組合 | |
| JPWO1996032101A1 (ja) | 癌転移抑制剤 | |
| JPWO1992004028A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| WO2022025831A1 (en) | Pharmaceutical compositions for injection comprising tulathromycin | |
| WO1992011247A1 (fr) | Composition anticancereuse et compose | |
| AU730172B2 (en) | 8a-azalides as veterinary antimicrobial agents | |
| JP5570429B2 (ja) | デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法 | |
| US8124593B2 (en) | Methods of treatment using sapacitabine | |
| US20160095925A1 (en) | Stable formulation of azacitidine or salts thereof and their process for preparation | |
| CN113631166A (zh) | 用于治疗癌症的口服给药的伊立替康和P-gp抑制剂的治疗组合 |